2025 年全球糖疗法市场报告

预计未来几年糖科学治疗市场将快速成长。到 2029 年，这一数字将成长至 3,610.9 亿美元，复合年增长率为 17.4%。预测期内的增长可归因于对糖生物学知识的不断扩展、精准医疗方法、对免疫疗法的兴趣日益浓厚、对罕见疾病研究的资金增加以及糖生物标誌物的出现。预测期内的关键趋势包括糖工程在肿瘤学中的应用不断扩大、糖工程在治疗性蛋白质增强中的应用、糖工程在免疫肿瘤学中的应用、糖工程在罕见和遗传疾病中的应用以及糖药物的监管考虑。

糖尿病盛行率的上升预计将推动糖尿治疗市场的成长。糖尿病是一种慢性疾病，会损害人体调节血糖（葡萄糖）水平的能力。糖尿病患者的糖基化变化已被发现，这可能导致胰岛素阻抗和其他代谢问题。特定的聚醣模式可以作为诊断糖尿病、预测病情进展和监测治疗反应的生物标记。例如，2022年3月，总部位于比利时、提供糖尿病盛行率详细资料和见解的全球资源机构IDF糖尿病地图集预测，全球糖尿病患者数量将从2030年的6.43亿增加到2045年的7.83亿，增加1.4亿人。因此，糖尿病盛行率的不断上升正在推动糖科学治疗市场的扩张。

癌症发生率的上升将推动糖治疗市场的成长。癌症的特征是细胞增殖和扩散不受控制，糖疗法已在治疗中得到应用。这些治疗方法针对并改变细胞表面的特定糖分子，旨在影响关键的细胞间相互作用、信号通路和免疫反应，从而抑制肿瘤生长并提高癌症治疗的效果。例如，根据美国癌症协会报道，预计2023年美国女性肝癌新病例数将从2022年的12,660例增加到13,230例。因此，癌症发生率的上升是推动糖治疗市场成长的关键因素。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第 4 章 市场：宏观经济情景，包括利率、通膨、地缘政治、新冠疫情以及復苏对市场的影响

第五章 全球成长分析与策略分析框架

• 全球糖疗法 PESTEL 分析（政治、社会、技术、环境、法律、驱动因素、限制因素）
• 最终用途产业分析
• 全球糖疗法市场：成长率分析
• 全球糖疗法市场表现：规模与成长，2019 年至 2024 年
• 全球糖疗法市场预测：2024-2029 年及 2034 年规模与成长
• 全球糖疗法总目标市场 (TAM)

第六章 市场细分

• 全球糖疗法市场：按类别、表现和预测，2019-2024 年、2024-2029 年、2034 年
• 孤立
• 合成
• 全球糖科学治疗市场结构、绩效与预测，2019-2024 年、2024-2029 年、2034 年
• 糖蛋白
• 靶向唾液酸
• 蛋白聚醣
• 靶向Glico
• 糖基磷脂酰肌醇 (GPI) 锚定蛋白和肝素基聚醣
• 针对醣鞘脂
• 其他结构
• 全球糖科学治疗市场（按作用机制、性能和预测）2019-2024 年、2024-2029 年、2034 年
• 抑制神经氨酸酶
• 它抑制肝素酶和选择素，并阻断生长因子与硫酸肝素的相互作用。
• 促红血球生成素和酵素替代疗法 (ERT)
• 组织胞浆素原原激活剂
• 抑制葡萄糖神经酰胺合成酶
• 白细胞介素1, 2, 3
• β 和 γ干扰素
• 其他作用机制
• 全球糖科学治疗市场（按适应症、表现和预测），2019-2024 年、2024-2029 年、2034 年
• 血栓症和化学预防
• 贫血
• 抗沾黏、抗发炎
• 白内障
• 高雪氏症
• MPS-1 和 IV
• 癌症
• 阿兹海默症
• 甲型流感和乙型流感
• 其他适应症
• 全球糖疗法市场，独立细分市场，按类型、实际和预测，2019-2024 年、2024-2029 年、2034 年
• 天然聚醣
• 聚醣衍生物
• 糖蛋白
• 全球糖疗法市场、合成细分市场、类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 化学合成聚醣
• 改性聚醣
• 糖肽

第七章 区域和国家分析

• 全球糖科学治疗市场：按地区、表现和预测，2019-2024 年、2024-2029 年、2034 年
• 全球糖科学治疗市场：按国家、表现和预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第 17 章 德国市场

第 18 章 法国市场

第 19 章：义大利市场

第 20 章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第 25 章：加拿大市场

第26章 南美洲市场

第 27 章：巴西市场

第28章 中东市场

第 29 章：非洲市场

第 30 章竞争格局与公司概况

• 糖疗法市场：竞争格局
• 糖疗法市场：公司简介
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

• Merck KGaA
• ICON plc
• Agilent Technologies Inc.
• AMS Bio
• Shimadzu Corporation
• Waters Corporation
• Bruker Corporation
• BioMarin Pharmaceutical Inc.
• Bio-Techne Corp.
• Promega Corporation
• Halozyme Therapeutics Inc.
• Takara Bio Inc.
• Vector Laboratories
• New England Biolabs Inc.
• Protalix Biotherapeutics Inc.

第 32 章 全球市场竞争基准化分析与仪表板

第33章 重大併购

第 34 章 近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

• 2029 年糖疗法市场：提供新机会的国家
• 2029 年糖疗法市场：提供新机会的细分市场
• 2029 年糖疗法市场：成长策略
  • 基于市场趋势的策略
  • 竞争对手的策略

第 36 章 附录

Glycomic therapeutics involves the application of glycomics-based approaches in the field of therapeutic development. The glycome, which constitutes the complete set of glycans in a cell or organism, plays a crucial role in understanding the intricate nature of biological systems and their implications for health and disease. Glycans are involved in diverse biological processes, including cell signaling, immune responses, and the development of diseases.

The primary types of glycomic therapeutics fall into two classes isolated and synthetic. Isolated glycomic therapy focuses on the study and analysis of glycans in isolation, delving into the structural and functional characterization of individual glycan molecules. Synthetic glycomic therapy involves the use of artificially created glycans or glycan-based molecules for diagnosing and treating various diseases or medical conditions. These therapies target different structures such as glycoproteins, sialic acid, proteoglycans, glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins, heparin-based glycans, glycosphingolipids, and others. The mode of action varies, including inhibiting neuraminidase, heparanase, selectins, blocking interactions between growth factors and heparan sulfate, and applications in erythropoietin and enzyme replacement therapy (ERT), tissue plasminogen activator, inhibiting glucosylceramide synthase, and targeting interleukins, interferons, among others. These therapies are employed for indications such as thrombosis and chemoprophylaxis, anemia, anti-adhesive and anti-inflammatory purposes, cataracts, Gaucher's disease, MPS-1 and IV, cancer, Alzheimer's disease, influenza types A and B, and more.

The glycomic therapeutics market research report is one of a series of new reports from The Business Research Company that provides glycomic therapeutics market statistics, including glycomic therapeutics industry global market size, regional shares, competitors with a glycomic therapeutics market share, detailed glycomic therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the glycomic therapeutics industry. This glycomic therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glycomic therapeutics market size has grown rapidly in recent years. It will grow from $164.71 billion in 2024 to $190.03 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to increased awareness of glycan significance, rise in chronic diseases, drug development for rare diseases, collaborations in glycomics research

The glycomic therapeutics market size is expected to see rapid growth in the next few years. It will grow to $361.09 billion in 2029 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to expanding knowledge of glycan biology, precision medicine approaches, rising interest in immunotherapy, increased funding for rare diseases research, emergence of glycan biomarkers. Major trends in the forecast period include expansion of glycomic applications in oncology, glycoengineering for enhanced therapeutic proteins, inclusion of glycomics in immuno-oncology, glycomics in rare and genetic disorders, regulatory considerations for glycomic drugs.

The rising prevalence of diabetes is anticipated to propel the growth of the glycomic therapeutics market. Diabetes is a chronic condition that impairs the body's ability to regulate blood sugar (glucose) levels. In individuals with diabetes, changes in glycans have been noted, which may lead to insulin resistance and other metabolic issues. Specific glycan patterns can act as biomarkers for diagnosing diabetes, forecasting its progression, and monitoring treatment responses. For example, in March 2022, the IDF Diabetes Atlas, a Belgium-based global resource that provides detailed data and insights on diabetes prevalence, projected that the global number of diabetes cases would rise from 643 million in 2030 to 783 million by 2045, representing an increase of 140 million cases. Thus, the growing prevalence of diabetes is driving the expansion of the glycomic therapeutics market.

The rising incidence of cancer is poised to drive the growth of the glycomic therapeutics market. Cancer, characterized by uncontrolled cell growth and spread, sees applications of glycomic therapeutics in treatment. These therapeutics target and modify specific sugar molecules on cell surfaces, influencing crucial cellular interactions, signaling pathways, and immune responses, with the goal of inhibiting tumor growth and enhancing the effectiveness of cancer therapies. For example, in 2023, the estimated number of new cases of liver cancer in females in the United States increased from 12,660 in 2022 to 13,230 in 2023, as reported by the American Cancer Society. Therefore, the increasing prevalence of cancer is a key factor driving the growth of the glycomic therapeutics market.

Product innovation stands out as a prominent trend gaining traction in the glycomic therapeutics market. Key players in the glycomic therapeutics sector are strategically investing in the development of cutting-edge technologies and innovative solutions to fortify their market position. For example, in April 2022, Glenmark Pharmaceuticals Limited, an Indian-based pharmaceutical company dedicated to discovering advanced therapies, introduced a novel fixed-dose combination (FDC) featuring a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This innovative combination aims to enhance glycemic control and reduce insulin resistance in patients with type 2 diabetes.

Leading companies in the glycomic therapeutics sector are actively engaged in the creation of groundbreaking technological solutions, such as screening kits, to advance glycobiology research and exploration. A screening kit is a pre-packaged set of tools and materials designed for a preliminary test to detect the presence or absence of a specific substance, condition, or property. For instance, in July 2022, Vector Laboratories, a US-based provider of glycomic solutions, launched Glysite Scout Glycan screening kits. These kits, fully integrated for immunofluorescence, facilitate the detection of glycan expression in tissue sections, allowing researchers to profile and characterize complex glycans in biological systems and identify major surface glycan motifs in a sample.

In May 2022, Halozyme Therapeutics, a US-based biotechnology company, completed the acquisition of Antares Pharma Inc. for $960 million. This strategic move bolstered Halozyme's pipeline portfolio of novel treatments utilizing advanced drug delivery methods, enhancing safety, efficacy, convenience, tolerability, and patient comfort and adherence. Antares Pharma Inc. is a US-based pharmaceutical firm.

Major companies operating in the glycomic therapeutics market include F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., GlycoMar Limited

North America was the largest region in the glycomic therapeutics in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glycomic therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glycomic therapeutics market consists of sales of investigational glycomic therapeutics and therapeutic glycomic that target glycans or glycan-related pathways for the diagnosis and treatment of diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glycomic Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glycomic therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glycomic therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glycomic therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Class: Isolated; Synthetic
• 2) By Structures: Glycoproteins; Targeting Sialic Acid; Proteoglycans; Targeting Glycosaminoglycans; Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans; Targeting Glycosphingolipids; Other Structures
• 3) By Mode Of Action: Inhibits Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons; Other Mode Of Action
• 4) By Indications: Thrombosis And Chemoprophylaxis; Anemia; Anti-Adhesive And Anti-Inflammatory; Cataracts; Gaucher's Disease; Mps-1 And IV; Cancer; Alzheimer's Disease; Influenza Type A And B; Other Indications
• Subsegments:
• 1) By Isolated: Natural Glycans; Glycan Derivatives; Glycoproteins
• 2) By Synthetic: Chemically Synthesized Glycans; Recombinant Glycans; Glycopeptides
• Companies Mentioned: F Hoffmann-La Roche Ltd.; Bayer AG; Sanofi SA; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Glycomic Therapeutics Market Characteristics

3. Glycomic Therapeutics Market Trends And Strategies

4. Glycomic Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Glycomic Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Glycomic Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Glycomic Therapeutics Market Growth Rate Analysis
• 5.4. Global Glycomic Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Glycomic Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Glycomic Therapeutics Total Addressable Market (TAM)

6. Glycomic Therapeutics Market Segmentation

• 6.1. Global Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Isolated
• Synthetic
• 6.2. Global Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glycoproteins
• Targeting Sialic Acid
• Proteoglycans
• Targeting Glycosaminoglycans
• Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin-Based Glycans
• Targeting Glycosphingolipids
• Other Structures
• 6.3. Global Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhibits Neuraminidase
• Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate
• Erythropoietin and Enzyme Replacement Therapy (ERT)
• Tissue Plasminogen Activator
• Inhibits Glucosylceramide Synthase
• Interleukin 1, 2, and 3
• Beta and Gamma Interferons
• Other Mode of Action
• 6.4. Global Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thrombosis and Chemoprophylaxis
• Anemia
• Anti-Adhesive and Anti-Inflammatory
• Cataracts
• Gaucher's Disease
• MPS-1 and IV
• Cancer
• Alzheimer's Disease
• Influenza Type A and B
• Other Indications
• 6.5. Global Glycomic Therapeutics Market, Sub-Segmentation Of Isolated, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natural Glycans
• Glycan Derivatives
• Glycoproteins
• 6.6. Global Glycomic Therapeutics Market, Sub-Segmentation Of Synthetic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemically Synthesized Glycans
• Recombinant Glycans
• Glycopeptides

7. Glycomic Therapeutics Market Regional And Country Analysis

• 7.1. Global Glycomic Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Glycomic Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glycomic Therapeutics Market

• 8.1. Asia-Pacific Glycomic Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glycomic Therapeutics Market

• 9.1. China Glycomic Therapeutics Market Overview
• 9.2. China Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glycomic Therapeutics Market

• 10.1. India Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glycomic Therapeutics Market

• 11.1. Japan Glycomic Therapeutics Market Overview
• 11.2. Japan Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glycomic Therapeutics Market

• 12.1. Australia Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glycomic Therapeutics Market

• 13.1. Indonesia Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glycomic Therapeutics Market

• 14.1. South Korea Glycomic Therapeutics Market Overview
• 14.2. South Korea Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glycomic Therapeutics Market

• 15.1. Western Europe Glycomic Therapeutics Market Overview
• 15.2. Western Europe Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glycomic Therapeutics Market

• 16.1. UK Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glycomic Therapeutics Market

• 17.1. Germany Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glycomic Therapeutics Market

• 18.1. France Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glycomic Therapeutics Market

• 19.1. Italy Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glycomic Therapeutics Market

• 20.1. Spain Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glycomic Therapeutics Market

• 21.1. Eastern Europe Glycomic Therapeutics Market Overview
• 21.2. Eastern Europe Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glycomic Therapeutics Market

• 22.1. Russia Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glycomic Therapeutics Market

• 23.1. North America Glycomic Therapeutics Market Overview
• 23.2. North America Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glycomic Therapeutics Market

• 24.1. USA Glycomic Therapeutics Market Overview
• 24.2. USA Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glycomic Therapeutics Market

• 25.1. Canada Glycomic Therapeutics Market Overview
• 25.2. Canada Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glycomic Therapeutics Market

• 26.1. South America Glycomic Therapeutics Market Overview
• 26.2. South America Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glycomic Therapeutics Market

• 27.1. Brazil Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glycomic Therapeutics Market

• 28.1. Middle East Glycomic Therapeutics Market Overview
• 28.2. Middle East Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glycomic Therapeutics Market

• 29.1. Africa Glycomic Therapeutics Market Overview
• 29.2. Africa Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glycomic Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Glycomic Therapeutics Market Competitive Landscape
• 30.2. Glycomic Therapeutics Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Glycomic Therapeutics Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. ICON plc
• 31.3. Agilent Technologies Inc.
• 31.4. AMS Bio
• 31.5. Shimadzu Corporation
• 31.6. Waters Corporation
• 31.7. Bruker Corporation
• 31.8. BioMarin Pharmaceutical Inc.
• 31.9. Bio-Techne Corp.
• 31.10. Promega Corporation
• 31.11. Halozyme Therapeutics Inc.
• 31.12. Takara Bio Inc.
• 31.13. Vector Laboratories
• 31.14. New England Biolabs Inc.
• 31.15. Protalix Biotherapeutics Inc.

32. Global Glycomic Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glycomic Therapeutics Market

34. Recent Developments In The Glycomic Therapeutics Market

35. Glycomic Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Glycomic Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Glycomic Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Glycomic Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer